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recovery after chemotherapy, 61% of the apheresis procedures
performed after chemotherapy-GF occurred when WBC was 20
compared to 21% of those performed after GF alone (P 0.0001).
With GF alone, mobilization is optimal after 4-5 days of therapy
when WBC is likely to be 20. We conclude that mobilizing
patients with the combination of chemotherapy and GF rather
than GF alone is likely to lead to leukapheresis being performed
when theWBC count is in a range that results in optimum CD34
cell CE. Autologous stem cells should be mobilized with chemo-
therapy-GF rather than GF alone if this is clinically feasible.
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A LONG TERM FOLLOW UP STUDY OF AUTOLOGOUS TRANSPLANTA-
TION FOR FOLLICULAR LYMPHOMA: A SINGLE CENTER EXPERIENCE
Ganguly, S., Deauna-Limayo, D., Divine, C.L., Bodensteiner, D.C.,
Cook, J.D., Lewis, J.L., Skikne, B.S. University of Kansas Medical
Center, Kansas City, KS
Appropriate timing of transplant in the management of follicular
lymphoma (FL) is not clear. We retrospectively evaluated our
experience of autologous transplantation in patients with FL from
1991 to 2003. Seventeen males and 7 females (n  24) of median
age 47.5 years (range, 28-64 years) were treated. Three patients
were in ﬁrst remission. Twenty one patients were salvaged after
relapse with second line chemotherapy. Of these, 14 were in CR or
very good PR at the time of transplantation, and 7 patients were
transplanted with active disease. Bone marrow was used in 6 pa-
tients as the source of stem cells prior to 1995 and peripheral blood
stem cells were used in 18 patients. The median CD34 cell dose
was 2.97  106/kg (range, 2.22-7.49  106/kg). Twenty-three of
24 patients engrafted (96%). Median time for neutrophil recovery
was 11.5 days (range, 9-35 days) and 15 days (range, 10-40 days) for
platelets. Median duration of follow up was 6 years (range, 7
month-8 years). Of the 24 patients, 6 had died. One patient died
from transplant related pulmonary complication. Overall survival
(OS) and disease free survival (DFS) of all evaluable patients were
71.6% and 40%. Median duration of response was 4.3 years. OS
and DFS in patients transplanted in CR were 80% and 57%. For
those transplanted with disease, a complete response was achieved
in 43% of patients, with the OS and DFS of 57% and 19 %
respectively. Status at transplantation was not a signiﬁcant variable
for survival (p 0.3). Three patients developed moderate to severe
treatment related toxicity; 2 with Grade III mucositis and 1 with
life threatening infection. In our experience, high dose therapy
with autologous stem cell transplantation in patients with high risk
or relapsed/refractory FL has little toxicity and appears to be
effective. Those with more advanced disease may require addi-
tional approaches to achieve and maintain remission.
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NON-MELPHALAN BASED CONDITIONING REGIMENS FOR TANDEM
AUTOGRAFTS IN MULTIPLE MYELOMA PATIENTS
Moreb, J.S., Pumphrey, P., Khan, S.A., Leather, H., Finiewicz, K.J.,
Reddy, V.S., Wingard, J.R. University of Florida, Gainesville, FL
Autologous stem cell transplantation (ASCT) has become a stan-
dard therapy for multiple myeloma (MM) patients. In the current
study we evaluated the toxicity and efﬁcacy of tandem autografts
for MM patients using non-melphalan based conditioning regi-
mens. Patients with stage II and III MM were enrolled in the study
after exhibiting response to induction therapy. The treatment plan
was designed to harvest a dose of 10  106 peripheral blood
CD34 cells/Kg ideal body weight (IBW) for the planned 2
transplants; however, a 2nd ASCT would be pursued only if CR has
not been achieved after the 1st ASCT. The 1st conditioning regi-
men included Busulfan 0.75 mg/Kg PO q6h for 16 doses on days
-8 through -5, Etoposide 10mg/Kg IV on days -4 to -2, and
Cyclosphosphamide 60 mg/Kg IV on days -3 and -2. The condi-
tioning regimen for the 2nd ASCT included 96 hour continuous
infusion of Cyclophosphamide (6 gr/m2) followed by total body
irradiation of 600 cGy in 4 fractions over 2 days followed by
reinfusion of stem cell product. Thus far, 21 patients have been
enrolled, median age of 56 years with median of 191 days from
diagnosis to 1st ASCT. All patients completed stem cell harvest
successfully. Total of 11 patients did not proceed to 2nd ASCT: 7
patients refused 2nd ASCT, 3 patients had CR after 1st ASCT, and
1 patient was disqualiﬁed due to drug induced psychosis during 1st
ASCT. Two patients are currently undergoing 2nd ASCT. Eight
patients completed tandem autografts. Median CD34 cell dose
and engraftment were similar for both transplants. Median time
between the 2 ASCTs was 107 days (range 91-145). One patient
with history of gastric bypass died due to liver failure 7 months
after 2nd ASCT. Another patient who completed one ASCT died
due to disease progression (PD) at 806 days after diagnosis. Overall
3 patients had CR and 3 had very good PR (VGPR) after 1st ASCT
(29%), while 5 achieved CR and 1 VGPR after 2nd ASCT with
total of 9/21 (43%) with CRVGPR. At the time of data analysis,
5 of 11 patients who completed only one ASCT showed PD at a
median time of 306 days, while only 3 of 8 patients completing the
2nd ASCT had PD at a median time of 562 days. In conclusion,
tandem autologous transplants result in higher proportion of MM
patients achieving CR, and non-melphalan based conditioning
regimens seem to be effective and safe, however a large number of
patients remain unwilling to proceed to the 2nd ASCT, mainly
because of economical/social reasons.
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FILGRASTIM (GCSF) IS BENEFICIAL AFTER AUTOLOGOUS PERIPHERAL
BLOOD GRAFTS WITH HIGH CD34 CELL CONTENT
Boulmay, B.1, Pazzalia, A.1, Leather, H.L.2, Sugrue, M.2, Wingard,
J.R.1 1. College of Medicine, University of Florida, Gainesville, FL; 2.
Shands at the University of Florida, Gainesville, FL
The 2000 ASCO guidelines recommend the use of colony stim-
ulating factors (CSFs) after autologous peripheral blood stem cell
transplantation (aPBSCT); however, the need for CSFs for pa-
tients (pts) with adequate CD34 cell content in their grafts has
not been established. Prior to 9/01, we initiated GCSF 5mcg/kg of
IBW beginning on D6 only for pts with CD34 doses of less
than 6  106/kg; since 9/01, that threshold was reduced to 4.5 
106/kg. Methods: We conducted a retrospective review of 43
aPBSCT pts from 9/99 through 5/03 with cell doses between
4.5-6  106/kg, 20 of whom had received GCSF (CSF) and 23 of
whom had not (w/o CSF). The groups were matched for age, sex,
diagnosis, prior chemotherapies, conditioning regimens, and mo-
bilization regimens. T-test was used to analyze the data. Results:
CSF pts had signiﬁcantly earlier ANC engraftment, shorter dura-
tion of neutropenia, shorter hospital stays, and fewer days of IV
antibiotics, as shown below in Table. A signiﬁcant difference was
not found for median days of fever, 1 in CSF pts vs 2 in pts w/o
CSF (p 0.31), or median day of platelet engraftment, 13.5 (range
10-74) vs 17 (range 11-30), p  0.29. Signiﬁcantly more pts with
prior radiation therapy (RT) were in the group w/o CSF than in
the CSF group (8 vs 1, p 0.02); however, RT was not found to be
a risk factor for delayed engraftment, prolonged neutropenia, or
length of stay. Conclusion: CSF use in aPBSCT pts with CD34
cell dose 6  106/kg results in earlier engraftment, shorter
neutropenia, and shorter hospital stay. Based on the average
wholesale price of GCSF and the daily cost of hospitalization for
aPBSCT pts, the cost of using GCSF in this population is $1500
per patient vs $4400 for 3 extra days of hospital stay. CSFs should
therefore be used post-aPBSCT in pts with CD34 cell dose6
106/kg.
Table. Effect of G-CSF on Time to Engraftment, Time to Discharge,
Days of Neutropenia and Days of Antibiotic Therapy
Parameter CSF w/o CSF P Value
Median day to ANC > 100
(range) 11 (8-13) 13 (9-15) <0.001
Median day to ANC > 500 11 (10-14) 15 (9-20) <0.001
Median day of discharge 12 (11-18) 15 (12-32) 0.0087
Days of neutropenia 8 (6-15) 12 (8-16) <0.001
Days of IV antibiotics 6 (0-12) 8 (0-13) 0.03
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